Oncotarget · 2017 · 24 citations · 9 references
MedicineOncologyOtolaryngologyCarcinogenesisNeoplasiaSurgical OncologyLaryngeal CancerMalignant NeoplasmsSquamous Cell CarcinomaGlottic Cancer SurgeryKaplan-meier Survival EstimatesLaryngeal Squamous Cell Carcinoma
// Ping Chen 1, * , Wenbin Yu 2, * , Junwei Huang 1 , Hongbo Xu 1 , Guojun Li 3, 4 , Xiaohong Chen 1 , Zhigang Huang 1 1 Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck surgery, Peking University Cancer Hospital & Institute, Houston, TX 77030, USA 3 Department of Head and Neck Surgery, Houston, TX 77030, USA 4 Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA * These authors contributed equally to this work and co-first authors Correspondence to: Zhigang Huang, email: enthzg@trhos.com Xiaohong Chen, email: trchxh@163.com Keywords: differentiation, laryngeal carcinoma, prognosis, staging, survival Received: November 18, 2016 Accepted: January 11, 2017 Published: January 20, 2017 ABSTRACT To compare survival outcomes between patients with poorly differentiated versus well-differentiated glottic squamous cell carcinoma (GSCC). Fifty-five patients with well-differentiated newly diagnosed GSCC were pair-matched to 55 patients with poorly differentiated GSCC according to age, sex, year of diagnosis, overall stage, treatment (surgery type, neck dissection, surgical margin, and chemoradiation), smoking, and alcohol use. Survival analysis was performed using Kaplan-Meier estimates, and matched-pair survival was estimated using the Cox proportional hazards regression model. Patients with well-differentiated GSCC had significantly better overall survival (OS) ( P = 0.001), disease-specific survival (DSS) ( P < 0.001), and disease-free survival (DFS) ( P = 0.003) than patients with poorly differentiated GSCC. Moreover, matched-pair analysis indicated that increased differentiation was associated with a significantly reduced risk of overall death (HR, 0.18; 95% confidence interval [CI], 0.07–0.46), death owing to disease (HR, 0.16; 95% CI, 0.05–0.45), and disease recurrence (HR, 0.17; 95% CI, 0.07–0.41), and these risks were reduced approximately 4-fold, 3.7-fold, and 9-fold, respectively, after adjustment for cancer-associated variables. Survival differed significantly between the well-differentiated and poorly differentiated GSCC patients after adjustment for cancer prognosis-associated variables. Thus, identifying potential differences in the molecular characteristics between these two groups of patients would help to further stratify these patients and ensure appropriate individualized treatment decisions. Basing treatment strategies on the level of differentiation may improve survival.
9
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
Power and sample size calculations
William D. Dupont, W. Dale Plummer · Controlled Clinical Trials · 1990 · 2.1K citations
Johannes A. Langendijk, Ben J. Slotman, I. van der Waal et al. · Cancer · 2005 · 133 citations · Full text
Pieter Schoen, Gerry M. Raghoebar, J. Bouma et al. · International Journal of Oral and Maxillofacial Surgery · 2007 · 130 citations
Dentistry, Oncology, Prosthodontics +16